NCT02915835已完成2 期
A Multi-center Randomized, Double Blind, Placebo-controlled, Pilot Study to Assess the Efficacy and Safety of Riociguat in Scleroderma - Associated Digital Ulcers
Dinesh Khanna, MD, MS5 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2016年9月最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 17
- 试验地点
- 5
- 主要终点
- Change From Baseline to End of Double-blind Treatment (Week 16) in Digital Ulcer Net Burden
研究概览
简要总结
The primary objective of this study is to provide preliminary data on the efficacy (digital ulcer net burden) and safety of riociguat administered 3 times daily (TID) in comparison to placebo in patients with scleroderma-associated digital ulcers
详细描述
This clinical trial is a US, multicenter, double-blind, randomized placebo-controlled, parallel- group study with a total of 20 participants planned to be randomized (approximately 10 participants to the riociguat group and 10 to the placebo group). In addition, a standardized wound care protocol will be followed by the investigators and digital photography will be taken of the cardinal ulcer.
The study will allow standard of care medications for the management of DU as background therapy. These may include calcium channel blockers, low dose aspirin, angiotensin enzyme inhibitors, etc. and will be determined by the participant's local physician.
The study design consists of three phases:
- Screening phase: up to 2 weeks
- Double-blind Treatment phase: 16 weeks of double-blind treatment, consisting of:
- Dose titration period of up to 8 weeks, and
- Stable dosing period of up to 8 weeks
- Open-label Extension phase for participants with active DU at the end of the double- blind treatment phase or development of an active DU within a month of completing double-blind phase, consisting of:
- Dose titration phase of up to 8 weeks
- Stable dosing period for 8 weeks
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent
- •Men or women aged 18 years and older
- •Diagnosis of Systemic sclerosis, as defined by 2013 American College of Rheumatology/ European Union League Against Rheumatism classification of SSc
- •Patients had to have at least one visible, active ischemic DU at baseline located at or distal to the proximal interphalangeal joint, and that developed or worsened within 8 weeks prior to screening. NOTE: Presence of eschar will not be considered an active ulcer
- •Females of reproductive potential (FRP) must have a negative, pre-treatment urine pregnancy test.
- •FRP must obtain monthly urine pregnancy tests during treatment and one month after treatment discontinuation. Post-menopausal women (defined as no menses for at least 1 year or post-surgical from bilateral oophorectomy) are not required to undergo a pregnancy test.
- •FRP and all non-vasectomized male participants must agree to use reliable contraception when sexually active. (For FRP's, 'Adequate contraception' is defined as any combination of at least 2 effective methods of birth control, of which at least one is a physical barrier (e.g., condoms with hormonal contraception or implants or combined oral contraceptives, certain intrauterine devices). This applies from the time of signing the informed consent form until one month after the last study drug administration.)
- •Oral corticosteroids (≤ 10 mg/day of prednisone or equivalent), nonsteroidal anti- inflammatory drugs (NSAIDs), angiotensin receptor blockers, angiotensin converting enzyme (ACE) inhibitors and calcium channel blockers are permitted if the participant is on a stable dose for ≥ 2 weeks prior to and including the baseline visit
- •Ability to comply with the clinical visits schedule and the study-related procedures.
排除标准
- •Active DU related to calcinosis (as assessed by clinical examination or radiographic evaluation at screening)
- •Medical and surgical history
- •Major surgery (including joint surgery) within 8 weeks prior to screening
- •Participants with a history of malignancy in the last 5 years other than non-melanoma skin cell cancers cured by local resection or carcinoma in situ
- •Hepatic-related criteria
- •Hepatic insufficiency classified as Child-Pugh C at screening (see Appendix 11.1 for classification table) at screening visit
- •Renal-related criteria
- •Estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73m2 (MDRD formula) or on dialysis at the screening visit
- •Cardiovascular-related criteria
- •Sitting systolic blood pressure < 95 mmHg at the screening visit
- •Sitting heart rate < 50 beats per minute (BPM) at the screening visit
- •Left ventricular ejection fraction < 40% prior to screening on echocardiogram done as part of clinical care
- •Pulmonary-related criteria
- •Active state of hemoptysis or pulmonary hemorrhage, including those events managed by bronchial artery embolization
- •Any history of bronchial artery embolization or massive hemoptysis within 3 months prior to screening. Massive hemoptysis being defined as acute bleeding >240 mL in a 24-hour period or recurrent bleeding >100 mL/d over several days
- •PAH requiring pharmacologic therapy.
- •Significant pulmonary disease with FVC ≤ 50% of predicted, or DLCO (uncorrected for hemoglobin ) ≤ 40% of predicted
- •Laboratory examinations
- •Participants with hemoglobin < 9.0 g/dL, white blood cell (WBC) count < 3000/mm3 (< 3 × 109/L), platelet count < 100,000/mm3 (< 3 × 109/L) at the screening visit
- •Prior and concomitant therapy
- •Concomitant use of nitrates or NO donors (such as amyl nitrate) in any form, including topical; phosphodiesterase (PDE) 5 (PDE5) inhibitors (such as sildenafil, tadalafil, vardenafil); and nonspecific PDE5 inhibitors (theophylline,dipyridamole). If the patient is on PDE5 inhibitors, a wash out of 3 days is required for sildenafil and 7 days for tadalafil or vardenafil prior to the baseline visit
- •Concomitant Endothelin receptor antagonist
- •Patients who are actively smoking at time of consent. (Quit date of two weeks prior to screening acceptable)
- •Pregnant or breastfeeding women
- •Any other condition or therapy that would make the participant unsuitable for this study and will not allow participation for the full planned study period
- •Participation in another clinical study with an investigational drug or medical device within 30 days prior to randomization (phase I-III clinical studies)
研究组 & 干预措施
riociguat
Active Comparator
Riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
干预措施: Riociguat (Drug)
Placebo
Placebo Comparator
Matching placebo tablets: 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg matching placebo tablet.
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline to End of Double-blind Treatment (Week 16) in Digital Ulcer Net Burden
时间窗: Baseline to Week 16
Digital ulcer net burden is defined as the total number of "active" and indeterminate digital ulcers at an assessment. Active ulcers are defined as having a denuded area with defined border and loss of epithelialization, loss of epidermis and dermis. An indeterminate ulcer is defined as denudation that could not be visualized and no other clinical features of activity. A healed ulcer has complete re-epithelialization.
次要结局
- Proportion of Participants With New Active and Indeterminate DU(s) Over the Course of the Double-blind Period(Baseline to Week 16)
- Proportion of Participants Who Develop Pressure Ulcers at Distal Interphalangeal (DIP) Location Over the Course of the Double-blind Period.(Baseline to Week 16)
- Proportion of Participants Who Develop Pressure Ulcers at Proximal Interphalangeal (PIP) Location Over the Course of the Double-blind Period.(Baseline to Week 16)
- Proportion of Participants Who Develop Pressure Ulcers at Metacarpophalangeal (MCPs) Location Over the Course of the Double-blind Period.(Baseline to Week 16)
- Proportion of Participants With Healing of All DUs at Baseline by Week 16(Week 16)
- Proportion of Participants With Healing of Their Cardinal DU by Week 16(Week 16)
- Proportion of Participants With no DUs at Week 16(Week 16)
- Proportion of Participants Who Develop Pressure Ulcers at the Elbows Over the Course of the Double-blind Period.(Baseline to Week 16)
- Proportion of Participants With Healing of All Pressure Ulcers at the Distal Interphalangeal (DIP) Over the Course of the Double-blind Period.(Baseline to Week 16)
- Proportion of Participants With Healing of All Pressure Ulcers at the Proximal Interphalangeal (PIP) Over the Course of the Double-blind Period.(Baseline to Week 16)
- Proportion of Participants With Healing of All Pressure Ulcers at the Metacarpophalangeal (MCPs) Over the Course of the Double-blind Period.(Baseline to Week 16)
- Proportion of Participants With Healing of All Pressure Ulcers at the Elbows Over the Course of the Double-blind Period.(Baseline to Week 16)
- Time to Healing of Cardinal DU(Baseline to Week 16)
- Time to Healing of All Baseline DU(Baseline to Week 16)
- Time to Development of New ('Active' or 'Indeterminate') DU(Baseline to Week 16)
- Change From Baseline to Week 16 in Raynaud's Condition Score(Baseline to Week 16)
- Change From Baseline to Week 16 in Number of Raynaud's Attacks/Day(Baseline to Week 16)
- Change From Baseline to Week 16 in Duration of Raynaud's Attacks(Baseline to Week 16)
- Change From Baseline to Week 16 in Patient's Assessment of Pain During a Raynaud's Attack(Baseline to Week 16)
- Change From Baseline to Week 16 in Patient's Assessment of Numbness During a Raynaud's Attack(Baseline to Week 16)
- Change From Baseline to Week 16 in Patient's Assessment of Tingling During a Raynaud's Attack(Baseline to Week 16)
- Change From Baseline to Week 16 in Physician's Assessment of Severity of Raynaud's Disease(Baseline to Week 16)
- Change From Baseline to Week 16 in Physician's Assessment of Severity of Digital Ulcers(Baseline to Week 16)
- Change From Baseline to Week 16 in Patient's Assessment of Severity of Digital Ulcers(Baseline to Week 16)
- Change From Baseline to Week 16 in HAQ-DI Dressing and Grooming(Baseline to Week 16)
- Change From Baseline to Week 16 in Patient's Assessment of Severity of Raynaud's Disease(Baseline to Week 16)
- Change From Baseline to Week 16 in PROMIS-29 Physical Function(Baseline/Week 16)
- Change From Baseline to Week 16 in PROMIS-29 Anxiety(Baseline to Week 16)
- Change From Baseline to Week 16 in PROMIS-29 Depression(Baseline to Week 16)
- Change From Baseline to Week 16 in PROMIS-29 Pain Interference(Baseline to Week 16)
- Change From Baseline to Week 16 in PROMIS-29 Pain Intensity(Baseline to Week 16)
- Change From Baseline to Week 16 in Patient's Global Assessment for Overall Disease.(Baseline to Week 16)
- Change From Baseline to Week 16 in PROMIS-29 Fatigue(Baseline to Week 16)
- Change From Baseline to Week 16 in Physician's Global Assessment for Overall Disease.(Baseline to Week 16)
- Change From Baseline to Week 16 in PROMIS-29 Sleep Disturbance(Baseline/Week 16)
- Change From Baseline to Week 16 in PROMIS-29 Ability to Participate in Social Roles and Activities(Baseline to Week 16)
- Change From Baseline to Week 16 in Overall HAQ-DI Score(Baseline to Week 16)
- Change From Baseline to Week 16 in HAQ-DI Reach(Baseline to Week 16)
- Change From Baseline to Week 16 in HAQ-DI Eating(Baseline to Week 16)
- Change From Baseline to Week 16 in HAQ-DI Hygiene(Baseline to Week 16)
- Change From Baseline to Week 16 in HAQ-DI Arising(Baseline to Week 16)
- Change From Baseline to Week 16 in HAQ-DI Grip(Baseline to Week 16)
- Change From Baseline to Week 16 in HAQ-DI Walking(Baseline to Week 16)
- Change From Baseline to Week 16 in HAQ-DI Common Daily Activities (IADL).(Baseline to Week 16)
- Change From Baseline to Week 16 in HAQ-DI Composite Score for Hand Function(Baseline to Week 16)
- Change From Baseline to Week 16 in Total Hand Disability in Systemic Sclerosis-DU (HDISS-DU) Score(Baseline to Week 16)
- Change From Baseline to Week 16 in Scleroderma-HAQ-DI Visual Analogue Scales (VAS) Assessing Burden of Digital Ulcers(Baseline to Week 16)
- Change From Baseline to Week 16 in Scleroderma-HAQ-DI Visual Analogue Scales (VAS) Assessing Raynaud's Disease(Baseline to Week 16)
- Change From Baseline to Week 16 in Scleroderma-HAQ-DI Visual Analogue Scales (VAS) Assessing Gastrointestinal Involvement(Baseline to Week 16)
- Change From Baseline to Week 16 in Scleroderma-HAQ-DI Visual Analogue Scales (VAS) Assessing Breathing(Baseline to Week 16)
- Change From Baseline to Week 16 in Scleroderma-HAQ-DI Visual Analogue Scales (VAS) Assessing Overall Disease,(Baseline to Week 16)
- Proportion of Participants Who Experience Digital Ischemia Requiring Intravenous Prostacyclin or Digital Gangrene or Amputation During the Trial.(Baseline to Week 16)
- Proportion of Participants Who Develop Osteomyelitis During The Trial(Baseline to Week 16)
- Change From Baseline to Week 16 in Vascular Biomarker VEGF in the Plasma(Baseline and Week 16)
- Change From Baseline to Week 16 in Vascular Biomarker tPA in the Plasma(Baseline and Week 16)
- Change From Baseline to Week 16 in Vascular Biomarker sE-Selectin in the Plasma(Baseline and Week 16)
- Change From Baseline to Week 16 in Vascular Biomarker BFGF in the Plasma(Baseline and Week 16)
- Change From Baseline to Week 16 in Vascular Biomarker VCAM-1 in the Plasma(Baseline and Week 16)
- Change From Baseline to Week 16 in Vascular Biomarker ICAM in the Plasma(Baseline and Week 16)
研究者
Dinesh Khanna, MD, MS
Professor of Rheumatology/ Internal Medicine
University of Michigan
研究点 (5)
Loading locations...
相似试验
已完成
2 期
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic DermatitisAtopic DermatitisNCT01756898Daiichi Sankyo370
已完成
2 期
Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative IleusIleusNCT05056935Newsoara Biopharma Co., Ltd.131
已完成
2 期
A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel ResectionIleusPost-Operative AdhesionsNCT02836470Palisade Bio112
已完成
3 期
Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)Diabetes Mellitus, Type 2NCT00106704Merck Sharp & Dohme LLC441
已完成
2 期
Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung DiseaseCystic FibrosisNCT00103714Merck Sharp & Dohme LLC72